298 related articles for article (PubMed ID: 15713554)
1. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
Rezapkin G; Martin J; Chumakov K
Biologicals; 2005 Mar; 33(1):29-39. PubMed ID: 15713554
[TBL] [Abstract][Full Text] [Related]
2. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
Rezapkin G; Dragunsky E; Chumakov K
Biologicals; 2005 Mar; 33(1):17-27. PubMed ID: 15713553
[TBL] [Abstract][Full Text] [Related]
3. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
Sawyer LA; McInnis J; Albrecht P
Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
[TBL] [Abstract][Full Text] [Related]
5. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
[TBL] [Abstract][Full Text] [Related]
6. Intratypic differentiation of poliovirus strains by enzyme-linked immunosorbent assay (ELISA): poliovirus type 1.
Glikmann G; Moynihan M; Petersen I; Vestergaard BF
Dev Biol Stand; 1983; 55():199-208. PubMed ID: 6203794
[TBL] [Abstract][Full Text] [Related]
7. Repertoire of antibodies against type 1 poliovirus in human sera.
Rezapkin G; Neverov A; Cherkasova E; Vidor E; Sarafanov A; Kouiavskaia D; Dragunsky E; Chumakov K
J Virol Methods; 2010 Nov; 169(2):322-31. PubMed ID: 20691212
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
9. Mapping of type 1 poliovirus neutralization epitopes.
Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
[TBL] [Abstract][Full Text] [Related]
10. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
[TBL] [Abstract][Full Text] [Related]
11. Structural studies of virus-antibody immune complexes (poliovirus type I): Characterization of the epitopes in 3D.
Bannwarth L; Girerd-Chambaz Y; Arteni AA; Guigner JM; Lemains J; Ronzon F; Manin C; Vénien-Bryan C
Mol Immunol; 2015 Feb; 63(2):279-86. PubMed ID: 25146483
[TBL] [Abstract][Full Text] [Related]
12. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
[TBL] [Abstract][Full Text] [Related]
13. Antigenic structure of poliovirus in inactivated vaccines.
Ferguson M; Wood DJ; Minor PD
J Gen Virol; 1993 Apr; 74 ( Pt 4)():685-90. PubMed ID: 7682250
[TBL] [Abstract][Full Text] [Related]
14. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.
Wood DJ; Heath AB; Kersten GF; Hazendonk T; Lantinga M; Beuvery EC
Biologicals; 1997 Mar; 25(1):59-64. PubMed ID: 9167009
[TBL] [Abstract][Full Text] [Related]
15. [Application of ELISA for screening McAb against type III polioviruses and its antigenic analysis].
Gu FZ; Wang SH; Sun YY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Oct; 7(5):359-63. PubMed ID: 2421926
[No Abstract] [Full Text] [Related]
16. Development of inactivated poliovirus vaccine derived from Sabin strains.
Simizu B; Abe S; Yamamoto H; Tano Y; Ota Y; Miyazawa M; Horie H; Satoh K; Wakabayashi K
Biologicals; 2006 Jun; 34(2):151-4. PubMed ID: 16679028
[TBL] [Abstract][Full Text] [Related]
17. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
18. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.
Westdijk J; Brugmans D; Martin J; van't Oever A; Bakker WA; Levels L; Kersten G
Vaccine; 2011 Apr; 29(18):3390-7. PubMed ID: 21397718
[TBL] [Abstract][Full Text] [Related]
19. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of an ELISA kit made in our laboratory for intratypic discrimination of poliovirus type 1 strains isolated from acute flask paralysis].
Ozkaya E; Arita M
Mikrobiyol Bul; 2002 Jan; 36(1):71-7. PubMed ID: 12476769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
